TY - JOUR
T1 - Relationship between mood episode and employment status of outpatients with bipolar disorder
T2 - Retrospective cohort study from the multicenter treatment survey for bipolar disorder in psychiatric clinics (musubi) project
AU - Konno, Yusuke
AU - Fujino, Yoshihisa
AU - Ikenouchi, Atsuko
AU - Adachi, Naoto
AU - Kubota, Yukihisa
AU - Azekawa, Takaharu
AU - Ueda, Hitoshi
AU - Edagawa, Koji
AU - Katsumoto, Eiichi
AU - Goto, Eiichiro
AU - Hongo, Seiji
AU - Kato, Masaki
AU - Tsuboi, Takashi
AU - Yasui-Furukori, Norio
AU - Nakagawa, Atsuo
AU - Kikuchi, Toshiaki
AU - Watanabe, Koichiro
AU - Yoshimura, Reiji
N1 - Funding Information:
Yusuke Konno, Yoshihisa Fujino, Atsuko Ikenouchi, Naoto Adachi declare no Conflict of Interests for this article. Yukihisa Kubota has received consultant fees from Pfizer and Meiji-Seika Pharma and speaker’s honoraria from Meiji-Seika Pharma, Eli Lilly, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Otsuka Pharmaceutical, and Eisai. Takaharu Azekawa has received speaker’s honoraria from Eli Lilly, Otsuka Pharmaceutical, and Pfizer. Hitoshi Ueda has received manuscript fees or speaker’s honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Yoshitomi Yakuhin. Koji Edagawa has received speaker’s honoraria from Eli Lilly, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Kyowa and Yoshitomi Yakuhin. Eiichi Katsumoto has received speaker’s honoraria from Daiichi Sankyo, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, and UCB. Eiichiro Goto has received manuscript fees or speaker’s honoraria from Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma. Seiji Hongo has received manuscript fees or speaker’s honoraria from Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Dainippon Pharma, and Yoshitomi Yakuhin. Masaki Kato has received grant funding from the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation and the Japan Research Foundation for Clinical Pharmacology, and speaker’s honoraria from Dainippon-Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithKline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical and Ono Pharmaceutical. Takashi Tsuboi has received consultant fees from Pfizer and speaker’s honoraria from Eli Lilly, Meiji-Seika Pharma, MSD, Janssen Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Yoshitomi Yakuhin, Mochida Pharmaceutical, Otsuka Pharmaceutical, Kyowa Pharmaceutical, and Takeda Pharmaceutical. Norio Yasui-Furukori has received grant/ research support or honoraria from, and received speaker’s
Publisher Copyright:
© 2021 Konno et al.
PY - 2021
Y1 - 2021
N2 - Objective: The objective of this study was to clarify the relationship between mood episode and employment in patients with bipolar disorder to help improve their employment status. Methods: All medical records of patients with bipolar disorder who visited 176 member clinics of the Japanese Association of Neuro-Psychiatric Clinics in September-October 2016 were investigated in September-October 2017. Details of the medical care received were investigated using a survey sheet, which included employment status. Odds ratios of mood episodes for employment status were analyzed using a logistic regression model. Results: Among patients aged 60 years or less, 2292 described their occupation. On univariate analysis, odds ratios were statistically significant for depressive episode (OR=2.68 [1.50-4.78] p=0.001) and manic episode (OR=2.64 [1.07-6.47] p=0.034), whereas no significant difference was noted for mixed episode (OR=1.72 [0.69-4.33] p=0.246). On multivariate analysis, odds ratios were statistically significant for depressive episode (OR=2.16 [1.13-4.13], p=0.020) and manic episode (OR=3.55 [1.36-9.25], p=0.010), whereas no significant difference was noted for mixed episode (OR=1.83 [0.65-5.14] p=0.254). Conclusion: Employment status among these patients with bipolar disorder receiving outpatient treatment was 43.5%. Compared to remission episodes, manic and depressive episodes were associated with a higher risk of unemployment.
AB - Objective: The objective of this study was to clarify the relationship between mood episode and employment in patients with bipolar disorder to help improve their employment status. Methods: All medical records of patients with bipolar disorder who visited 176 member clinics of the Japanese Association of Neuro-Psychiatric Clinics in September-October 2016 were investigated in September-October 2017. Details of the medical care received were investigated using a survey sheet, which included employment status. Odds ratios of mood episodes for employment status were analyzed using a logistic regression model. Results: Among patients aged 60 years or less, 2292 described their occupation. On univariate analysis, odds ratios were statistically significant for depressive episode (OR=2.68 [1.50-4.78] p=0.001) and manic episode (OR=2.64 [1.07-6.47] p=0.034), whereas no significant difference was noted for mixed episode (OR=1.72 [0.69-4.33] p=0.246). On multivariate analysis, odds ratios were statistically significant for depressive episode (OR=2.16 [1.13-4.13], p=0.020) and manic episode (OR=3.55 [1.36-9.25], p=0.010), whereas no significant difference was noted for mixed episode (OR=1.83 [0.65-5.14] p=0.254). Conclusion: Employment status among these patients with bipolar disorder receiving outpatient treatment was 43.5%. Compared to remission episodes, manic and depressive episodes were associated with a higher risk of unemployment.
KW - Continuous employment
KW - Japan
KW - Mood disorder
KW - Occupational health
UR - http://www.scopus.com/inward/record.url?scp=85115646609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115646609&partnerID=8YFLogxK
U2 - 10.2147/NDT.S322507
DO - 10.2147/NDT.S322507
M3 - Article
AN - SCOPUS:85115646609
SN - 1176-6328
VL - 17
SP - 2867
EP - 2876
JO - Neuropsychiatric Disease and Treatment
JF - Neuropsychiatric Disease and Treatment
ER -
